Funding
$550K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Existing therapies for conditions like Inflammatory Bowel Disease (IBD), cancer, and oral health often have limited effectiveness due to the unique and dynamic nature of each individual's gut microbiome and its impact on their immune system. Current diagnostic methods may not fully capture the complex interplay between the microbiome and the host's immune response, leading to suboptimal treatment strategies.
Solution
NostraBiome offers microbiome intelligence panels that analyze a patient's dynamic inflammatory microbiome signature (DMIS) to personalize and enhance existing therapies. Using metagenomic sequencing and AI-driven analysis of over 400,000 medical papers and clinical references, NostraBiome identifies the unique ways in which a patient's microbiome impacts their immune response. Based on this analysis, the platform generates tailored recommendations, including lifestyle adjustments, nutritional guidance, supplement recommendations, and, if necessary, antiviral or antimicrobial interventions, to modulate the microbiome and improve treatment outcomes. The company's approach aims to improve the efficacy of existing treatments by reducing the unnecessary immune load and promoting a more efficient immune response.
Target Audience
NostraBiome's primary target audience includes individuals with digestive conditions like IBD and IBS, cancer patients undergoing therapy, and individuals seeking to improve their oral health, as well as the medical experts and professionals who treat them.
Features
- At-home microbiome collection kit for convenient sample collection
- Metagenomic sequencing to analyze the composition and structure of the gut microbiome
- AI-driven analysis to identify the dynamic inflammatory microbiome signature (DMIS) and predict the microbiome's impact on the immune system
- Personalized recommendations, including lifestyle adjustments, nutritional guidance, and supplement recommendations
- Identification of potential pathogens and metabolites produced by gut bacteria
- Integration of medical history and health status to refine recommendations
- Monitoring of key metrics, such as DMIS and Predictive Microbiome Immune Load (PMIL), to track progress
- Clinically certified facilities and bioinformatics pipeline to ensure data accuracy and compliance